ORIGINAL ARTICLE

Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs

  1. B.E. Elewski1,*,
  2. M.A. Ghannoum2,
  3. P. Mayser3,
  4. A.K. Gupta4,
  5. H.-C. Korting5,
  6. R.J. Shouey6,
  7. D.R. Baker7,
  8. P.A. Rich8,
  9. M. Ling9,
  10. S. Hugot10,
  11. B. Damaj11,
  12. J. Nyirady12,
  13. K. Thangavelu10,
  14. M. Notter10,
  15. A. Parneix-Spake12,
  16. B. Sigurgeirsson13

Article first published online: 20 DEC 2011

DOI: 10.1111/j.1468-3083.2011.04373.x

Issue

Journal of the European Academy of Dermatology and Venereology

Journal of the European Academy of Dermatology and Venereology

Volume 27, Issue 3, pages 287–294, March 2013

Additional Information

How to Cite

Elewski, B.E., Ghannoum, M.A., Mayser, P., Gupta, A.K., Korting, H.-C., Shouey, R.J., Baker, D.R., Rich, P.A., Ling, M., Hugot, S., Damaj, B., Nyirady, J., Thangavelu, K., Notter, M., Parneix-Spake, A. and Sigurgeirsson, B. (2013), Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. Journal of the European Academy of Dermatology and Venereology, 27: 287–294. doi: 10.1111/j.1468-3083.2011.04373.x

Author Information

  1. 1

    Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, USA

  2. 2

    Center for Medical Mycology, Case Western Reserve University, Cleveland and University Hospitals of Cleveland, Cleveland, OH, USA

  3. 3

    Center of Dermatology and Andrology, Justus Liebig University, Giessen, Germany

  4. 4

    Division of Dermatology, Department of Medicine, University of Toronto, Canada

  5. 5

    Department of Dermatology and Allergy, Ludwig Maximilian University, Munich, Germany

  6. 6

    Harrisonburg Foot Clinic, Harrisonburg, VA, USA

  7. 7

    Allergy, Asthma & Dermatology Research Center, LLC, Lake Oswego, OR, USA

  8. 8

    Oregon Dermatology and Research Center, Portland, OR, USA

  9. 9

    Medaphase Inc., Newnan, GA, USA

  10. 10

    Novartis Pharma AG, Basel, Switzerland

  11. 11

    NexMed (USA), Inc., San Diego, CA, USA

  12. 12

    Novartis Pharmaceuticals Corp., East Hanover, NJ, USA

  13. 13

    Department of Dermatology, University of Iceland, Reykjavik, Iceland

* B.E. Elewski. E-mail:beelewski@aol.com

  1. Conflict of interest H.C. Korting has previously collaborated with Novartis in the development of topicals containing terbinafine, and with Galderma concerning amorolfin-containing preparations. Drs’. P. Mayser, R. Shouey, A. Gupta and B. Sigurgeirsson have no conflict of interests. S. Hugot, M. Notter, K. Thangavelu, A. Parneix-Spake and J. Nyirady are employees of Novartis. Drs’ B.E. Elewski, P. Rich and M. Ling have received research grant fund from Novartis for the performing of the study. Dr B. Damaj is an employee of NexMed (USA), Inc. Dr D. Baker was a principal investigator at one of the research sites. Dr M. Ghannoum has accepted as a consultant for Novartis Pharmaceuticals.

  2. Funding sources Novartis Pharma AG, Basel, Switzerland.

Publication History

  1. Issue published online: 18 FEB 2013
  2. Article first published online: 20 DEC 2011
  3. Received: 29 May 2011; Accepted: 10 November 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (243K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (243K)